Tregzi is the second cell therapy to be approved by the FDA for use in the context of managing GVHD in HSCT patients, albeit ...

As the US relaxes an export ban on Anthropic's advanced AI tools, the company formally launched Claude Science, an AI ...

When it comes to global pharma pricing and market access, this moment is one of unprecedented change. As policy initiatives like Most Favoured Nations (MFN) and the EU’s Joint Clinical Assessment ...

In its second acquisition of the week, Ipsen will take control of Memo Therapeutics and a first-in-class drug for BK ...

Women with polyendocrine metabolic ovarian syndrome (PMOS) in the UK should get diagnosed sooner and be offered an annual review of their condition, according to new guidance from NICE. Draft guidance ...